VVOS
Income statement / Annual
Last year (2023), Vivos Therapeutics, Inc.'s total revenue was $13.80 M,
a decrease of 13.87% from the previous year.
In 2023, Vivos Therapeutics, Inc.'s net income was -$13.58 M.
See Vivos Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$13.80 M
|
$16.02 M
|
$16.89 M
|
$13.07 M
|
$11.39 M
|
$3.79 M
|
| Cost of Revenue |
$6.15 M |
$6.01 M |
$4.28 M |
$2.65 M |
$2.74 M |
$1.08 M |
| Gross Profit |
$7.65 M |
$10.02 M |
$12.60 M |
$10.41 M |
$8.66 M |
$2.71 M |
| Gross Profit Ratio |
0.55 |
0.63 |
0.75 |
0.8 |
0.76 |
0.71 |
| Research and Development
Expenses |
$100,000.00
|
$200,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$22.48 M
|
$29.04 M
|
$25.79 M
|
$16.09 M
|
$16.17 M
|
$9.27 M
|
| Selling & Marketing
Expenses |
$2.47 M
|
$5.34 M
|
$5.55 M
|
$2.31 M
|
$2.31 M
|
$1.16 M
|
| Selling, General &
Administrative Expenses |
$24.85 M
|
$34.38 M
|
$31.34 M
|
$18.40 M
|
$18.48 M
|
$10.44 M
|
| Other Expenses |
-$65,000.00 |
$669,000.00 |
$733,000.00 |
$717,865.00 |
$751,228.00 |
$610,673.00 |
| Operating Expenses |
$24.95 M |
$35.05 M |
$32.08 M |
$19.12 M |
$19.23 M |
$11.05 M |
| Cost And Expenses |
$31.10 M |
$41.06 M |
$36.36 M |
$21.78 M |
$21.97 M |
$12.13 M |
| Interest Income |
$0.00 |
$89,000.00 |
$117,000.00 |
$79,612.00 |
$21,133.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$1.19 M |
$14,000.00 |
$96,681.00 |
$137,876.00 |
$102,974.00 |
| Depreciation &
Amortization |
$621,000.00
|
$669,000.00
|
$733,000.00
|
$717,865.00
|
$751,228.00
|
$610,673.00
|
| EBITDA |
-$16.68 M
|
-$24.46 M
|
-$18.63 M
|
-$11.24 M
|
-$9.80 M
|
-$7.73 M
|
| EBITDA Ratio |
-1.21 |
-1.53 |
-1.1 |
-0.86 |
-0.86 |
-2.04 |
| Operating Income Ratio
|
-1.25
|
-1.56
|
-1.15
|
-0.67
|
-0.93
|
-2.2
|
| Total Other
Income/Expenses Net |
$3.71 M
|
$1.19 M
|
-$817,000.00
|
-$3.35 M
|
-$177,086.00
|
-$102,974.00
|
| Income Before Tax |
-$13.58 M |
-$23.85 M |
-$20.29 M |
-$12.06 M |
-$10.75 M |
-$8.44 M |
| Income Before Tax Ratio
|
-0.98
|
-1.49
|
-1.2
|
-0.92
|
-0.94
|
-2.23
|
| Income Tax Expense |
$453,105.00 |
-$1.19 M |
$5,000.00 |
-$3.23 M |
$137,876.00 |
$102,974.00 |
| Net Income |
-$13.58 M |
-$22.66 M |
-$20.29 M |
-$8.82 M |
-$10.89 M |
-$8.54 M |
| Net Income Ratio |
-0.98 |
-1.41 |
-1.2 |
-0.68 |
-0.96 |
-2.25 |
| EPS |
-11.14 |
-24.62 |
-23.89 |
-12.11 |
-14.97 |
-18.49 |
| EPS Diluted |
-11.14 |
-24.62 |
-23.89 |
-12.11 |
-14.97 |
-18.49 |
| Weighted Average Shares
Out |
$1.22 M
|
$920,484.00
|
$849,320.00
|
$728,378.00
|
$727,667.00
|
$461,926.00
|
| Weighted Average Shares
Out Diluted |
$1.22 M
|
$920,484.00
|
$849,320.00
|
$728,378.00
|
$727,667.00
|
$461,926.00
|
| Link |
|
|
|
|
|
|
